BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35. [DOI: 10.1136/gutjnl-2012-302830] [Cited by in Crossref: 448] [Cited by in F6Publishing: 414] [Article Influence: 49.8] [Reference Citation Analysis]
Number Citing Articles
1 Hung YK, Ho ST, Kuo CY, Chen MJ. In vitro effects of velvet antler water extracts from Formosan Sambar deer and red deer on barrier integrity in Caco-2 cell. Int J Med Sci 2021;18:1778-85. [PMID: 33746595 DOI: 10.7150/ijms.53599] [Reference Citation Analysis]
2 Melson J, Trikudanathan G, Abu Dayyeh BK, Bhutani MS, Chandrasekhara V, Jirapinyo P, Krishnan K, Kumta NA, Pannala R, Parsi MA, Sethi A, Trindade AJ, Watson RR, Maple JT, Lichtenstein DR. Video capsule endoscopy. Gastrointest Endosc 2021;93:784-96. [PMID: 33642034 DOI: 10.1016/j.gie.2020.12.001] [Reference Citation Analysis]
3 Yan B, Feagan B, Teriaky A, Mosli M, Mohamed R, Williams G, Yeung E, Yong E, Haig A, Sey M, Stitt L, Zou GY, Jairath V. Reliability of EUS indices to detect inflammation in ulcerative colitis. Gastrointest Endosc 2017;86:1079-87. [PMID: 28760533 DOI: 10.1016/j.gie.2017.07.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Morshedzadeh N, Shahrokh S, Aghdaei HA, Amin Pourhoseingholi M, Chaleshi V, Hekmatdoost A, Karimi S, Zali MR, Mirmiran P. Effects of flaxseed and flaxseed oil supplement on serum levels of inflammatory markers, metabolic parameters and severity of disease in patients with ulcerative colitis. Complementary Therapies in Medicine 2019;46:36-43. [DOI: 10.1016/j.ctim.2019.07.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
5 Salem MS, Melmed GY. The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet? Gastrointest Endosc Clin N Am 2019;29:437-46. [PMID: 31078246 DOI: 10.1016/j.giec.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tontini GE, Rath T, Neumann H. Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. World J Gastroenterol 2016; 22(3): 1246-1259 [PMID: 26811662 DOI: 10.3748/wjg.v22.i3.1246] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
7 Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016;65:1447-1455. [PMID: 26353983 DOI: 10.1136/gutjnl-2015-309903] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 15.5] [Reference Citation Analysis]
8 Lee YW, Lee KM, Lee JM, Chung YY, Kim DB, Kim YJ, Chung WC, Paik CN. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J Intern Med. 2019;34:72-80. [PMID: 29347813 DOI: 10.3904/kjim.2016.324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
9 Kavitt RT, Hirano I. Endoscopic assessment of eosinophilic esophagitis. Techniques in Gastrointestinal Endoscopy 2014;16:20-5. [DOI: 10.1016/j.tgie.2013.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Deng F, He S, Cui S, Shi Y, Tan Y, Li Z, Huang C, Liu D, Zhi F, Peng L. A Molecular Targeted Immunotherapeutic Strategy for Ulcerative Colitis via Dual-targeting Nanoparticles Delivering miR-146b to Intestinal Macrophages. Journal of Crohn's and Colitis 2019;13:482-94. [DOI: 10.1093/ecco-jcc/jjy181] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
11 Patel MM. Micro/nano-particulate drug delivery systems: a boon for the treatment of inflammatory bowel disease. Expert Opinion on Drug Delivery 2016;13:771-5. [DOI: 10.1517/17425247.2016.1166203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hirschmann S, Neurath MF. Top-down approach to biological therapy of Crohn's disease. Expert Opin Biol Ther 2017;17:285-93. [PMID: 28132526 DOI: 10.1080/14712598.2017.1287170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Cosín-Roger J, Ortiz-Masiá D, Calatayud S, Hernández C, Alvarez A, Hinojosa J, Esplugues JV, Barrachina MD. M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative colitis. PLoS One 2013;8:e78128. [PMID: 24167598 DOI: 10.1371/journal.pone.0078128] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
14 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang K, Jin X, Chen Y, Song Z, Jiang X, Hu F, Conlon MA, Topping DL. Polyphenol-Rich Propolis Extracts Strengthen Intestinal Barrier Function by Activating AMPK and ERK Signaling. Nutrients 2016;8:E272. [PMID: 27164138 DOI: 10.3390/nu8050272] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
16 Parker A, Vaux L, Patterson AM, Modasia A, Muraro D, Fletcher AG, Byrne HM, Maini PK, Watson AJM, Pin C. Elevated apoptosis impairs epithelial cell turnover and shortens villi in TNF-driven intestinal inflammation. Cell Death Dis 2019;10:108. [PMID: 30728350 DOI: 10.1038/s41419-018-1275-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
17 Matusiewicz M, Neubauer K, Bednarz-Misa I, Gorska S, Krzystek-Korpacka M. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis. World J Gastroenterol 2017; 23(22): 4039-4046 [PMID: 28652656 DOI: 10.3748/wjg.v23.i22.4039] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
18 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
19 Lenz P, Bettenworth D, Krausewitz P, Brückner M, Ketelhut S, von Bally G, Domagk D, Kemper B. Digital holographic microscopy quantifies the degree of inflammation in experimental colitis. Integrative Biology 2013;5:624-30. [DOI: 10.1039/c2ib20227a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
20 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
21 Chernavskaia O, Heuke S, Vieth M, Friedrich O, Schürmann S, Atreya R, Stallmach A, Neurath MF, Waldner M, Petersen I, Schmitt M, Bocklitz T, Popp J. Beyond endoscopic assessment in inflammatory bowel disease: real-time histology of disease activity by non-linear multimodal imaging. Sci Rep 2016;6:29239. [PMID: 27406831 DOI: 10.1038/srep29239] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
22 Theocharidou E, Gossios TD, Giouleme O, Athyros VG, Karagiannis A. Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. Angiology 2014;65:284-93. [PMID: 23423851 DOI: 10.1177/0003319713477471] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
23 夏蜀娴, 缪应雷. HSF2和促炎症细胞因子在溃疡性结肠炎中的表达. 世界华人消化杂志 2014; 22(30): 4683-4690 [DOI: 10.11569/wcjd.v22.i30.4683] [Reference Citation Analysis]
24 Pagnini C, Di Paolo MC, Giordano M, Graziani MG. Histologic disease activity control as a therapeutic target in Crohn's disease patients: A word of caution. Dig Liver Dis 2020;52:591-2. [PMID: 32057685 DOI: 10.1016/j.dld.2020.01.003] [Reference Citation Analysis]
25 Maeda Y, Kudo SE, Ogata N, Mori Y, Misawa M, Homma M, Nemoto T, Ogawa M, Sasanuma S, Sato Y, Kataoka S, Kouyama Y, Sakurai T, Igarashi K, Ogawa Y, Kato K, Ichimasa K, Nakamura H, Kudo T, Hayashi T, Wakamura K, Baba T, Inoue H, Ohtsuka K. Endocytoscopic intramucosal capillary network changes and crypt architecture abnormalities can predict relapse in patients with an ulcerative colitis Mayo endoscopic score of 1. Dig Endosc 2020;32:1082-91. [PMID: 32073691 DOI: 10.1111/den.13655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology 2019;157:1019-1031.e7. [PMID: 31279870 DOI: 10.1053/j.gastro.2019.06.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
27 Dou W, Zhang J, Li H, Kortagere S, Sun K, Ding L, Ren G, Wang Z, Mani S. Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway. J Nutr Biochem 2014;25:923-33. [PMID: 24913217 DOI: 10.1016/j.jnutbio.2014.04.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
28 Buttó LF, Schaubeck M, Haller D. Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol 2015;6:555. [PMID: 26635787 DOI: 10.3389/fimmu.2015.00555] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
29 Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohns Colitis 2019;13:424-30. [PMID: 30445625 DOI: 10.1093/ecco-jcc/jjy184] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
30 Lim KJ, Lee SJ, Kim S, Lee SY, Lee MS, Park YA, Choi EJ, Lee EB, Jun HK, Cho JM. Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease. J Crohns Colitis. 2017;11:593-602. [PMID: 28453766 DOI: 10.1093/ecco-jcc/jjw183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
31 Lee HJ, Shin HS, Jang HW, Kim SW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlation between soluble triggering receptor expressed on myeloid cells-1 and endoscopic activity in intestinal Behçet's disease. Yonsei Med J 2014;55:960-6. [PMID: 24954324 DOI: 10.3349/ymj.2014.55.4.960] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
32 Neumann H, Kudo SE, Kiesslich R, Neurath MF. Advanced colonoscopic imaging using endocytoscopy. Dig Endosc. 2015;27:232-238. [PMID: 25311804 DOI: 10.1111/den.12395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
33 Li J, Leung WK. Colon capsule endoscopy for inflammatory bowel disease: Colon capsule endoscopy for IBD. Journal of Digestive Diseases 2018;19:386-94. [DOI: 10.1111/1751-2980.12614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis. J Crohns Colitis 2021:jjab135. [PMID: 34309658 DOI: 10.1093/ecco-jcc/jjab135] [Reference Citation Analysis]
35 Ohtsuka K, Takenaka K, Kitazume Y, Fujii T, Matsuoka K, Kimura M, Nagaishi T, Watanabe M. Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease. Intest Res 2016;14:120-6. [PMID: 27175112 DOI: 10.5217/ir.2016.14.2.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
36 Deuring JJ, de Haar C, Kuipers EJ, Peppelenbosch MP, van der Woude CJ. The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease. Int J Biochem Cell Biol 2013;45:798-806. [PMID: 23291352 DOI: 10.1016/j.biocel.2012.12.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
37 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
38 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 214] [Cited by in F6Publishing: 206] [Article Influence: 53.5] [Reference Citation Analysis]
39 Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, Eichner S, Li Y, Reilly N, Thakkar RB, Robinson AM, Lazar A. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:453-60. [PMID: 28129288 DOI: 10.1097/MIB.0000000000001021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 9.7] [Reference Citation Analysis]
40 Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Dig Liver Dis 2017;49:29-33. [PMID: 27866814 DOI: 10.1016/j.dld.2016.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
41 Kanazawa M, Takahashi F, Tominaga K, Abe K, Izawa N, Fukushi K, Nagashima K, Kanamori A, Takenaka K, Sugaya T, Iijima M, Takada A, Imai Y, Hiraishi H, Irisawa A. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open 2019;7:E568-75. [PMID: 30957007 DOI: 10.1055/a-0869-7619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
42 Jensen LB, Wahli T, McGurk C, Eriksen TB, Obach A, Waagbø R, Handler A, Tafalla C. Effect of temperature and diet on wound healing in Atlantic salmon (Salmo salar L.). Fish Physiol Biochem 2015;41:1527-43. [PMID: 26272065 DOI: 10.1007/s10695-015-0105-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
43 Ong C, Lim PT, Logarajah V, Liwanag MJ, Ang BX, Cher Y, Chiou FK, Kader A. Exclusive enteral nutrition with concomitant early thiopurine use was effective in maintaining steroid-free remission in a Southeast Asian cohort of children with Crohn's disease. BMC Gastroenterol 2018;18:185. [PMID: 30541458 DOI: 10.1186/s12876-018-0907-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Frey MR. Regenerating Reputations: Are Wnt and Myc the Good Guys After All? Dig Dis Sci 2016;61:327-9. [PMID: 26520110 DOI: 10.1007/s10620-015-3947-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Gong SS, Fan YH, Wang SY, Han QQ, Lv B, Xu Y, Chen X, He YE. Mucosa repair mechanisms of Tong-Xie-Yao-Fang mediated by CRH-R2 in murine, dextran sulfate sodium-induced colitis. World J Gastroenterol 2018; 24(16): 1766-1778 [PMID: 29713130 DOI: 10.3748/wjg.v24.i16.1766] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Aherne CM, Collins CB, Rapp CR, Olli KE, Perrenoud L, Jedlicka P, Bowser JL, Mills TW, Karmouty-Quintana H, Blackburn MR, Eltzschig HK. Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation. JCI Insight 2018;3:121521. [PMID: 30333323 DOI: 10.1172/jci.insight.121521] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
47 Teng X, Qi Y, Li J, Wu J. Effect of Exclusive Enteral Nutrition on Th17 Cells in Juvenile Rats with Inflammatory Bowel Disease. Inflammation 2021;44:261-9. [PMID: 32897457 DOI: 10.1007/s10753-020-01328-4] [Reference Citation Analysis]
48 Ampuero J, Rojas-Feria M, Castro-Fernández M, Millán-Lorenzo M, Guerrero-Jiménez P, Romero-Gómez M. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's Disease in clinical practice. J Gastroenterol Hepatol. 2015;Epub ahead of print. [PMID: 26173493 DOI: 10.1111/jgh.13039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
49 Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A, Krzystek-Korpacka M. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019;20. [PMID: 30621173 DOI: 10.3390/ijms20010166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
50 Flemming S, Luissint AC, Kusters DHM, Raya-Sandino A, Fan S, Zhou DW, Hasegawa M, Garcia-Hernandez V, García AJ, Parkos CA, Nusrat A. Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration. Mol Biol Cell 2020;31:407-18. [PMID: 31967937 DOI: 10.1091/mbc.E19-12-0692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
51 Fluxá D, Simian D, Flores L, Ibáñez P, Lubascher J, Figueroa C, Kronberg U, Pizarro G, Castro M, Piottante A, Vial MT, Quera R. Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis: Correlation in ulcerative colitis. Journal of Digestive Diseases 2017;18:634-41. [DOI: 10.1111/1751-2980.12546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Feagan BG, Sands BE, Rossiter G, Li X, Usiskin K, Zhan X, Colombel JF. Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. Gastroenterology 2018;154:61-64.e6. [PMID: 28847751 DOI: 10.1053/j.gastro.2017.08.035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
53 Cosín-Roger J, Ortiz-Masiá D, Calatayud S, Hernández C, Esplugues JV, Barrachina MD. The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD. Mucosal Immunol 2016;9:986-98. [PMID: 26601901 DOI: 10.1038/mi.2015.123] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 13.5] [Reference Citation Analysis]
54 Nguyen DL, Solaimani P, Nguyen ET, Jamal MM, Bechtold ML. Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease: a meta-analysis. European Journal of Gastroenterology & Hepatology 2014;26:1152-9. [DOI: 10.1097/meg.0000000000000178] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
55 Nakano T, Uchiyama K, Ushiroda C, Kashiwagi S, Toyokawa Y, Mizushima K, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Handa O, Ishikawa T, Takagi T, Konishi H, Naito Y, Itoh Y. Promotion of wound healing by acetate in murine colonic epithelial cell via c-Jun N-terminal kinase activation. J Gastroenterol Hepatol 2020;35:1171-9. [PMID: 31961456 DOI: 10.1111/jgh.14987] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Delaney J, Laws P, Wille-jørgensen P, Engel A. Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research? Colorectal Dis 2015;17:600-11. [DOI: 10.1111/codi.12882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
57 Du J, Du H, Chen H, Shen L, Zhang B, Xu W, Zhang Z, Chen C. Characteristics and prognosis of isolated small-bowel Crohn’s disease. Int J Colorectal Dis 2020;35:69-75. [DOI: 10.1007/s00384-019-03432-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Nakamura M, Hirooka Y, Watanabe O, Yamamura T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Goto H. A Retrospective Evaluation of the Utility of Capsule Endoscopy and Double-Balloon Endoscopy in Crohn's Disease. Gastroenterol Res Pract 2016;2016:1085027. [PMID: 26843856 DOI: 10.1155/2016/1085027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
59 Hart L, Chavannes M, Kherad O, Maedler C, Mourad N, Marcus V, Afif W, Bitton A, Lakatos PL, Brassard P, Bessissow T. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis. J Crohns Colitis 2020;14:46-52. [PMID: 31314884 DOI: 10.1093/ecco-jcc/jjz107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
60 Kucharski M, Karczewski J, Mańkowska-wierzbicka D, Karmelita-katulska K, Grzymisławski M, Kaczmarek E, Iwanik K, Rzymski P, Swora-cwynar E, Linke K, Dobrowolska A. Applicability of endoscopic indices in the determination of disease activity in patients with ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2016;28:722-30. [DOI: 10.1097/meg.0000000000000601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-biroulet L, Vuitton L, Boureille A, Blain A, Gay C, Koch S, Ambregna S, Vaurie F, François S, Martin B, Agouzal K, Boivineau L, Branche J, Gerard R, Benezech A, Aider B, Rouillon C, Perrod G, De Montigny S, Aygalenq P; The CLEAN Study Group. Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. Journal of Crohn's and Colitis 2019;13:1121-30. [DOI: 10.1093/ecco-jcc/jjz040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Lan A, Blachier F, Benamouzig R, Beaumont M, Barrat C, Coelho D, Lancha A Jr, Kong X, Yin Y, Marie JC, Tomé D. Mucosal healing in inflammatory bowel diseases: is there a place for nutritional supplementation? Inflamm Bowel Dis 2015;21:198-207. [PMID: 25208104 DOI: 10.1097/MIB.0000000000000177] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
63 Schlegel N, Boerner K, Waschke J. Targeting desmosomal adhesion and signalling for intestinal barrier stabilization in inflammatory bowel diseases-Lessons from experimental models and patients. Acta Physiol (Oxf) 2021;231:e13492. [PMID: 32419327 DOI: 10.1111/apha.13492] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
64 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 14.3] [Reference Citation Analysis]
66 Patnaude L, Mayo M, Mario R, Wu X, Knight H, Creamer K, Wilson S, Pivorunas V, Karman J, Phillips L, Dunstan R, Kamath RV, McRae B, Terrillon S. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci 2021;271:119195. [PMID: 33581125 DOI: 10.1016/j.lfs.2021.119195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-83. [PMID: 33359090 DOI: 10.1053/j.gastro.2020.12.031] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 51.0] [Reference Citation Analysis]
68 Ding S, Ma Y, Liu G, Yan W, Jiang H, Fang J. Lactobacillus brevis Alleviates DSS-Induced Colitis by Reprograming Intestinal Microbiota and Influencing Serum Metabolome in Murine Model. Front Physiol 2019;10:1152. [PMID: 31620010 DOI: 10.3389/fphys.2019.01152] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
69 Targownik LE, Sexton KA, Bernstein MT, Beatie B, Sargent M, Walker JR, Graff LA. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol. 2015;110:1001-12; quiz 1013. [PMID: 26077178 DOI: 10.1038/ajg.2015.147] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 13.7] [Reference Citation Analysis]
70 Knieling F, Waldner MJ. Light and sound - emerging imaging techniques for inflammatory bowel disease. World J Gastroenterol 2016; 22(25): 5642-5654 [PMID: 27433080 DOI: 10.3748/wjg.v22.i25.5642] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
71 Kim YG, Jang BI. The role of colonoscopy in inflammatory bowel disease. Clin Endosc 2013;46:317-20. [PMID: 23964327 DOI: 10.5946/ce.2013.46.4.317] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
72 Morimoto K, Watanabe K, Noguchi A, Miyazaki T, Nagami Y, Sugimori S, Kamata N, Sogawa M, Tanigawa T, Yamagami H, Shiba M, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T. Clinical impact of ultrathin colonoscopy for Crohn's disease patients with strictures. J Gastroenterol Hepatol 2015;30 Suppl 1:66-70. [PMID: 25827807 DOI: 10.1111/jgh.12739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
73 Mottet C, Schoepfer AM, Juillerat P, Cosnes J, Froehlich F, Kessler-brondolo V, Seibold F, Rogler G, Vavricka SR, Michetti P. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2016;22:2733-47. [DOI: 10.1097/mib.0000000000000923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
74 Xie Z, Wang Y, Yang G, Han J, Zhu L, Li L, Zhang S. The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease. Cell Death Dis 2021;12:79. [PMID: 33436549 DOI: 10.1038/s41419-021-03395-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 84] [Article Influence: 12.9] [Reference Citation Analysis]
76 Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment. ECCOJC 2016;10:1279-86. [DOI: 10.1093/ecco-jcc/jjw086] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
77 Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55. [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
78 Boumessid K, Barreau F, Mas E. How Can a Polymeric Formula Induce Remission in Crohn's Disease Patients? Int J Mol Sci 2021;22:4025. [PMID: 33919747 DOI: 10.3390/ijms22084025] [Reference Citation Analysis]
79 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 188] [Article Influence: 37.3] [Reference Citation Analysis]
80 Echarri A, Ollero V, Barreiro-de Acosta M, Fernández-villaverde A, Hernández V, Lorenzo A, Pereira S, Carpio D, Castro J. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. European Journal of Gastroenterology & Hepatology 2015;27:430-5. [DOI: 10.1097/meg.0000000000000296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Yokoyama K, Kobayashi K, Mukae M, Sada M, Koizumi W. Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis. Gastroenterol Res Pract. 2013;2013:192794. [PMID: 23762033 DOI: 10.1155/2013/192794] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
82 Sieczkowska J, Jarzębicka D, Meglicka M, Oracz G, Kierkus J. Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol 2016;9:729-35. [PMID: 27582886 DOI: 10.1177/1756283X16650155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 Quirós M, Nusrat A. Contribution of Wound-Associated Cells and Mediators in Orchestrating Gastrointestinal Mucosal Wound Repair. Annu Rev Physiol 2019;81:189-209. [PMID: 30354933 DOI: 10.1146/annurev-physiol-020518-114504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
84 Yan BM, Sey MSL, Belletrutti P, Brahm G, Guizzetti L, Jairath V. Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis. Endosc Int Open 2021;9:E1116-22. [PMID: 34327283 DOI: 10.1055/a-1481-8032] [Reference Citation Analysis]
85 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
86 Huynh E, Penney J, Caswell J, Li J. Protective Effects of Protegrin in Dextran Sodium Sulfate-Induced Murine Colitis. Front Pharmacol 2019;10:156. [PMID: 30873029 DOI: 10.3389/fphar.2019.00156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
87 Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. J Pediatr Gastroenterol Nutr 2017;64:955-61. [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
88 Hoffman JM, Baritaki S, Ruiz JJ, Sideri A, Pothoulakis C. Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. Am J Pathol. 2016;186:134-144. [PMID: 26597886 DOI: 10.1016/j.ajpath.2015.09.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
89 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y, OBSERV-IBD study group and the GETAID. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310-321. [PMID: 28593685 DOI: 10.1111/apt.14167] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 20.0] [Reference Citation Analysis]
90 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
91 Levin AD, Koelink PJ, Bloemendaal FM, Vos AC, D'Haens GR, van den Brink GR, Wildenberg ME. Autophagy Contributes to the Induction of Anti-TNF Induced Macrophages. J Crohns Colitis 2016;10:323-9. [PMID: 26417049 DOI: 10.1093/ecco-jcc/jjv174] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
92 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Reference Citation Analysis]
93 Cummins EP, Doherty GA, Taylor CT. Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest 2013;93:378-83. [PMID: 23419710 DOI: 10.1038/labinvest.2013.9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
94 Timmermans WM, van Laar JA, van der Houwen TB, Kamphuis LS, Bartol SJ, Lam KH, Ouwendijk RJ, Sparrow MP, Gibson PR, van Hagen PM, van Zelm MC. B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS One 2016;11:e0160103. [PMID: 27468085 DOI: 10.1371/journal.pone.0160103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
95 Tan Y, Guan Y, Sun Y, Zheng C. Correlation of Intestinal Mucosal Healing and Tight Junction Protein Expression in Ulcerative Colitis Patients. Am J Med Sci. 2019;357:195-204. [PMID: 30638599 DOI: 10.1016/j.amjms.2018.11.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
96 Yokoyama K, Kobayashi K, Mukae M, Sada M, Koizumi W. Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis. Gastroenterol Res Pract. 2013;2013:192794. [PMID: 23762033 DOI: 10.1155/2013/192794].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Cotti E, Mezzena S, Schirru E, Ottonello O, Mura M, Ideo F, Susnik M, Usai P. Healing of Apical Periodontitis in Patients with Inflammatory Bowel Diseases and under Anti–tumor Necrosis Factor Alpha Therapy. Journal of Endodontics 2018;44:1777-82. [DOI: 10.1016/j.joen.2018.09.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
98 Peterson CG, Lampinen M, Hansson T, Lidén M, Hällgren R, Carlson M. Evaluation of biomarkers for ulcerative colitis comparing two sampling methods: fecal markers reflect colorectal inflammation both macroscopically and on a cellular level. Scand J Clin Lab Invest 2016;76:393-401. [PMID: 27223407 DOI: 10.1080/00365513.2016.1185145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
99 Almeida-junior L, Curimbaba T, Chagas A, Quaglio A, Di Stasi L. Dietary intervention with green dwarf banana flour ( Musa sp. AAA) modulates oxidative stress and colonic SCFAs production in the TNBS model of intestinal inflammation. Journal of Functional Foods 2017;38:497-504. [DOI: 10.1016/j.jff.2017.09.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
100 Naganuma M, Kobayashi T, Nasuno M, Motoya S, Kato S, Matsuoka K, Hokari R, Watanabe C, Sakamoto H, Yamamoto H, Sasaki M, Watanabe K, Iijima H, Endo Y, Ichikawa H, Ozeki K, Tanida S, Ueno N, Fujiya M, Sako M, Takeuchi K, Sugimoto S, Abe T, Hibi T, Suzuki Y, Kanai T. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:1102-1111.e5. [PMID: 31394288 DOI: 10.1016/j.cgh.2019.07.054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
101 Gunji N, Katakura K, Abe K, Kawashima K, Fujiwara T, Onizawa M, Takahashi A, Ohira H. Upregulation of complement C1q reflects mucosal regeneration in a mouse model of colitis. Med Mol Morphol 2021;54:87-94. [PMID: 33029672 DOI: 10.1007/s00795-020-00266-2] [Reference Citation Analysis]
102 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
103 Buda A, Hatem G, Neumann H, D' Incà R, Mescoli C, Piselli P, Jackson J, Bruno M, Sturniolo GC. Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: A pilot study. Journal of Crohn's and Colitis 2014;8:304-11. [DOI: 10.1016/j.crohns.2013.09.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
104 Molander P, Kemppainen H, Ilus T, Sipponen T. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol 2020;55:34-40. [PMID: 31841064 DOI: 10.1080/00365521.2019.1701070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 White L, Saldin L, Keane T, Cramer M, Shakesheff K, Badylak S. 2.24 Hydrogels of Decellularized Matrix. Comprehensive Biomaterials II. Elsevier; 2017. pp. 532-41. [DOI: 10.1016/b978-0-12-803581-8.09313-9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
106 Shi HY, Ng SC, Tsoi KK, Wu JC, Sung JJ, Chan FK. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:47-54. [PMID: 24966092 DOI: 10.1586/17474124.2014.934359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
107 Sonoyama H, Kawashima K, Ishihara S, Kotani S, Fukuba N, Oka A, Kusunoki R, Tada Y, Mishima Y, Oshima N, Moriyama I, Yuki T, Onishi K, Kinoshita Y. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr 2019;64:265-70. [PMID: 31138962 DOI: 10.3164/jcbn.18-92] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
108 Gupta R, Chaudhary AR, Shah BN, Jadhav AV, Zambad SP, Gupta RC, Deshpande S, Chauthaiwale V, Dutt C. Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. Clin Exp Gastroenterol 2014;7:13-23. [PMID: 24493931 DOI: 10.2147/CEG.S51923] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
109 Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Pariente B, Pierik MJ, van der Woude CJ, D'Haens GRAM, Vermeire S, Oldenburg B; Dutch Initiative on Crohn and Colitis. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. Clin Gastroenterol Hepatol. 2020;18:1704-1718. [PMID: 31881273 DOI: 10.1016/j.cgh.2019.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
110 Piras V, Usai P, Mezzena S, Susnik M, Ideo F, Schirru E, Cotti E. Prevalence of Apical Periodontitis in Patients with Inflammatory Bowel Diseases: A Retrospective Clinical Study. J Endod. 2017;43:389-394. [PMID: 28231978 DOI: 10.1016/j.joen.2016.11.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
111 Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis. 2017;11:84-91. [PMID: 27466171 DOI: 10.1093/ecco-jcc/jjw132] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
112 Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016;50:733-741. [PMID: 26535480 DOI: 10.1097/mcg.0000000000000441] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
113 Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2018;. [PMID: 30130840 DOI: 10.5946/ce.2018.042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
114 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Brégeon J, Coron E, Da Silva AC, Jaulin J, Aubert P, Chevalier J, Vergnolle N, Meurette G, Neunlist M. Sacral nerve stimulation enhances early intestinal mucosal repair following mucosal injury in a pig model. J Physiol 2016;594:4309-23. [PMID: 26939757 DOI: 10.1113/JP271783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
116 Kim DH, Park SJ, Park JJ, Yun YH, Hong SP, Kim TI, Kim WH, Cheon JH. Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci. 2014;59:2514-2522. [PMID: 24838498 DOI: 10.1007/s10620-014-3197-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
117 Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases 2018; 6(15): 952-960 [PMID: 30568951 DOI: 10.12998/wjcc.v6.i15.952] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
118 Chiriac MT, Buchen B, Wandersee A, Hundorfean G, Günther C, Bourjau Y, Doyle SE, Frey B, Ekici AB, Büttner C, Weigmann B, Atreya R, Wirtz S, Becker C, Siebler J, Neurath MF. Activation of Epithelial Signal Transducer and Activator of Transcription 1 by Interleukin 28 Controls Mucosal Healing in Mice With Colitis and Is Increased in Mucosa of Patients With Inflammatory Bowel Disease. Gastroenterology 2017;153:123-138.e8. [PMID: 28342759 DOI: 10.1053/j.gastro.2017.03.015] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
119 Fukaura K, Iboshi Y, Ogino H, Ihara E, Nakamura K, Nishihara Y, Nishioka K, Chinen T, Iwasa T, Aso A, Goto A, Haraguchi K, Akiho H, Harada N, Ogawa Y. Mucosal Profiles of Immune Molecules Related to T Helper and Regulatory T Cells Predict Future Relapse in Patients With Quiescent Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1019-27. [PMID: 30668727 DOI: 10.1093/ibd/izy395] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
120 Takenaka K, Tominaga K, Kanazawa M, Fukushi K, Tanaka T, Kanamori A, Sugaya T, Tsuchida K, Iijima M, Goda K, Irisawa A. Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. Sci Rep 2019;9:17751. [PMID: 31780764 DOI: 10.1038/s41598-019-54369-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
121 Neubauer K, Matusiewicz M, Bednarz-Misa I, Gorska S, Gamian A, Krzystek-Korpacka M. Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD. Gastroenterol Res Pract 2018;2018:7265812. [PMID: 30147719 DOI: 10.1155/2018/7265812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
122 Hertati A, Hayashi S, Ogawa Y, Yamamoto T, Kadowaki M. Interleukin-4 Receptor α Subunit Deficiency Alleviates Murine Intestinal Inflammation In Vivo Through the Enhancement of Intestinal Mucosal Barrier Function. Front Pharmacol 2020;11:573470. [PMID: 33192516 DOI: 10.3389/fphar.2020.573470] [Reference Citation Analysis]
123 Moy MP, Kaplan JL, Moran CJ, Winter HS, Gee MS. MR Enterographic Findings as Biomarkers of Mucosal Healing in Young Patients With Crohn Disease. AJR Am J Roentgenol 2016;207:896-902. [PMID: 27351067 DOI: 10.2214/AJR.16.16079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
124 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
125 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
126 Moreno N, Ripollés T, Paredes JM, Ortiz I, Martínez MJ, López A, Delgado F, Moreno-osset E. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: Changes following treatment with immunomodulators and/or anti-TNF antibodies. J Crohns Colitis 2014;8:1079-87. [DOI: 10.1016/j.crohns.2014.02.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 9.4] [Reference Citation Analysis]
127 Malvão LDR, Madi K, Esberard BC, de Amorim RF, Silva KDS, Farias E Silva K, de Souza HSP, Carvalho ATP. Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. Medicine (Baltimore) 2021;100:e24058. [PMID: 33546007 DOI: 10.1097/MD.0000000000024058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
129 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
130 Noman M, Ferrante M, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts P, Vermeire S, Van Assche G. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. J Crohns Colitis. 2017;11:1085-1089. [PMID: 28369329 DOI: 10.1093/ecco-jcc/jjx048] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
131 Wittkopf N, Neurath MF, Becker C. Immune-epithelial crosstalk at the intestinal surface. J Gastroenterol 2014;49:375-87. [PMID: 24469679 DOI: 10.1007/s00535-013-0929-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
132 Scaldaferri F, Petito V, Lopetuso L, Bruno G, Gerardi V, Ianiro G, Sgambato A, Gasbarrini A, Cammarota G. Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm 2013;2013:391473. [PMID: 23737647 DOI: 10.1155/2013/391473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
133 Yoshino T, Yamakawa K, Nishimura S, Watanabe K, Yazumi S. The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res 2016;14:37-42. [PMID: 26884733 DOI: 10.5217/ir.2016.14.1.37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
134 Bao WL, Wu Q, Hu B, Sun D, Zhao S, Shen X, Cheng H, Shen W. Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis. Int J Nanomedicine 2021;16:345-57. [PMID: 33488076 DOI: 10.2147/IJN.S286392] [Reference Citation Analysis]
135 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 75] [Article Influence: 15.2] [Reference Citation Analysis]
136 Neumann H, Kiesslich R. Endomicroscopy and endocytoscopy in IBD. Gastrointest Endosc Clin N Am. 2013;23:695-705. [PMID: 23735111 DOI: 10.1016/j.giec.2013.03.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
137 Reinisch W, Gottlieb K, Colombel J, Danese S, Panaccione R, Panes J, Peyrin-biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology 2019;17:1673-1679.e1. [DOI: 10.1016/j.cgh.2018.10.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
138 Kirchgesner J, Nyboe Andersen N, Carrat F, Jess T, Beaugerie L. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut 2020;69:852-8. [DOI: 10.1136/gutjnl-2019-318932] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
139 Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, Staiano A, Escher J, Kolho KL, Paerregaard A, Martin de Carpi J, Veereman Wauters G, Koletzko S, Shevah O, Finnby L, Sladek M. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. Inflamm Bowel Dis 2014;20:278-85. [PMID: 24390062 DOI: 10.1097/01.MIB.0000437735.11953.68] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 8.8] [Reference Citation Analysis]
140 Du G, Xiong L, Li X, Zhuo Z, Zhuang X, Yu Z, Wu L, Xiao D, Liu Z, Jie M, Liu X, Luo G, Guo Z, Chen H. Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. Dev Cell 2020;53:169-184.e11. [PMID: 32243783 DOI: 10.1016/j.devcel.2020.03.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
141 Ekanayaka A, Anderson JT, Lucarotti ME, Valori RM, Shepherd NA. The isolated caecal patch lesion: a clinical, endoscopic and histopathological study. J Clin Pathol 2020;73:121-5. [DOI: 10.1136/jclinpath-2019-206146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Nowacki TM, Brückner M, Eveslage M, Tepasse P, Pott F, Thoennissen NH, Hengst K, Ross M, Bettenworth D. The Risk of Colorectal Cancer in Patients with Ulcerative Colitis. Dig Dis Sci 2015;60:492-501. [DOI: 10.1007/s10620-014-3373-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
143 Xu X, Yang W, Liang Q, Shi Y, Zhang W, Wang X, Meng F, Zhong Z, Yin L. Efficient and targeted drug/siRNA co-delivery mediated by reversibly crosslinked polymersomes toward anti-inflammatory treatment of ulcerative colitis (UC). Nano Res 2019;12:659-67. [DOI: 10.1007/s12274-019-2274-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
144 Krzystek-Korpacka M, Kempiński R, Bromke M, Neubauer K. Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. Diagnostics (Basel) 2020;10:E367. [PMID: 32498475 DOI: 10.3390/diagnostics10060367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
145 Chavannes M, Martinez-vinson C, Hart L, Kaniki N, Chao C, Lawrence S, Jacobson K, Hugot J, Viala J, Deslandres C, Jantchou P, Seidman EG. Management of Paediatric Patients With Medically Refractory Crohn’s Disease Using Ustekinumab: A Multi-Centred Cohort Study. Journal of Crohn's and Colitis 2019;13:578-84. [DOI: 10.1093/ecco-jcc/jjy206] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
146 Jiang XG, Sun K, Liu YY, Yan L, Wang MX, Fan JY, Mu HN, Li C, Chen YY, Wang CS, Han JY. Astragaloside IV ameliorates 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis implicating regulation of energy metabolism. Sci Rep 2017;7:41832. [PMID: 28150820 DOI: 10.1038/srep41832] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
147 Bang-Berthelsen CH, Holm TL, Pyke C, Simonsen L, Søkilde R, Pociot F, Heller RS, Folkersen L, Kvist PH, Jackerott M, Fleckner J, Vilién M, Knudsen LB, Heding A, Frederiksen KS. GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. Inflamm Bowel Dis 2016;22:2078-97. [PMID: 27542128 DOI: 10.1097/MIB.0000000000000847] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 11.3] [Reference Citation Analysis]
148 Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Moritou Y, Akita M, Takahashi S, Hori K, Harada K, Okada H, Yamamoto K. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 2014; 20(48): 18367-18374 [PMID: 25561804 DOI: 10.3748/wjg.v20.i48.18367] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
149 Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med 2014;20:313-8. [PMID: 24562382 DOI: 10.1038/nm.3462] [Cited by in Crossref: 235] [Cited by in F6Publishing: 197] [Article Influence: 33.6] [Reference Citation Analysis]
150 Chifflet S, Hernandez JA. The Epithelial Sodium Channel and the Processes of Wound Healing. Biomed Res Int 2016;2016:5675047. [PMID: 27493961 DOI: 10.1155/2016/5675047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
151 Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:525-41. [PMID: 25110257 DOI: 10.1016/j.gtc.2014.05.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
152 Bourgonje AR, Gabriëls RY, de Borst MH, Bulthuis MLC, Faber KN, van Goor H, Dijkstra G. Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. Antioxidants (Basel) 2019;8:E351. [PMID: 31480545 DOI: 10.3390/antiox8090351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
153 Lobatón T, López-garcía A, Rodríguez-moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's and Colitis 2013;7:e641-51. [DOI: 10.1016/j.crohns.2013.05.005] [Cited by in Crossref: 102] [Cited by in F6Publishing: 95] [Article Influence: 12.8] [Reference Citation Analysis]
154 Tontini GE, Vecchi M, Neurath MF, Neumann H. Review article: newer optical and digital chromoendoscopy techniques vs. dye-based chromoendoscopy for diagnosis and surveillance in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:1198-1208. [PMID: 24117471 DOI: 10.1111/apt.12508] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
155 Kotla NG, Rana S, Sivaraman G, Sunnapu O, Vemula PK, Pandit A, Rochev Y. Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives. Adv Drug Deliv Rev 2019;146:248-66. [PMID: 29966684 DOI: 10.1016/j.addr.2018.06.021] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
156 Hejl J, Theede K, Møllgren B, Madsen KV, Heidari A, Á Steig A, Fenger M. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract Lab Med 2018;10:10-4. [PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
157 Ogawa T, Ohda Y, Nagase K, Kono T, Tozawa K, Tomita T, Iimuro M, Hida N, Oshima T, Fukui H, Hori K, Watari J, Nakamura S, Miwa H. Evaluation of discomfort during colonoscopy with conventional and ultrathin colonoscopes in ulcerative colitis patients: Ultrathin colonoscope for UC patients. Digestive Endoscopy 2015;27:99-105. [DOI: 10.1111/den.12323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
158 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342. [PMID: 24751956 DOI: 10.1038/nri3661] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 1071] [Article Influence: 161.3] [Reference Citation Analysis]
159 Bai R, Sun D, Chen M, Shi X, Luo L, Yao Z, Liu Y, Ge X, Gao X, Hu GF, Zhou W, Sheng J, Xu Z. Myeloid cells protect intestinal epithelial barrier integrity through the angiogenin/plexin-B2 axis. EMBO J 2020;39:e103325. [PMID: 32510170 DOI: 10.15252/embj.2019103325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
160 Church PC, Greer MC, Cytter-Kuint R, Doria AS, Griffiths AM, Turner D, Walters TD, Feldman BM. Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease. Pediatr Radiol 2017;47:565-75. [PMID: 28283726 DOI: 10.1007/s00247-017-3790-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
161 Driscoll K, Deshpande A, Datta R, Ramakrishna W. Anti-inflammatory Effects of Northern Highbush Blueberry Extract on an In Vitro Inflammatory Bowel Disease Model. Nutrition and Cancer 2020;72:1178-90. [DOI: 10.1080/01635581.2019.1673449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Bourgonje AR, von Martels JZH, Gabriëls RY, Blokzijl T, Buist-Homan M, Heegsma J, Jansen BH, van Dullemen HM, Festen EAM, Ter Steege RWF, Visschedijk MC, Weersma RK, de Vos P, Faber KN, Dijkstra G. A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. Front Med (Lausanne) 2019;6:251. [PMID: 31772929 DOI: 10.3389/fmed.2019.00251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
163 Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(9): 886-907 [PMID: 33727776 DOI: 10.3748/wjg.v27.i9.886] [Reference Citation Analysis]
164 Moreau B, Clement P, Theoret Y, Seidman EG. Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD. Therap Adv Gastroenterol 2017;10:819-27. [PMID: 29147133 DOI: 10.1177/1756283X17733657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
165 Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, Delchier JC, Amiot A. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn’s disease: A retrospective study. Dig Liver Dis. 2014;46:695-700. [PMID: 24893686 DOI: 10.1016/j.dld.2014.04.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
166 Gong W, Guo K, Zheng T, Xie H, Li W, Li M, Hong Z, Ren H, Gu G, Wang G, Wu X, Ren J. JINLING (Judicious INdex of Luminal INflammation Grade) score, an effective indicator to assess inflammation severity in Crohn's disease. Eur J Gastroenterol Hepatol 2021;33:1049-54. [PMID: 33136728 DOI: 10.1097/MEG.0000000000001979] [Reference Citation Analysis]
167 Neumann H, Neurath MF. UCCIS—a reproducible tool to assess mucosal healing. Nat Rev Gastroenterol Hepatol 2012;9:692-4. [DOI: 10.1038/nrgastro.2012.198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
168 Okamoto R, Watanabe M. Investigating cell therapy for inflammatory bowel disease. Expert Opin Biol Ther 2016;16:1015-23. [PMID: 27113391 DOI: 10.1080/14712598.2016.1177019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
169 Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457-478. [PMID: 25110253 DOI: 10.1016/j.gtc.2014.05.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
170 Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol 2017; 15: 1557-1564. e1. [PMID: 28238954 DOI: 10.1016/j.cgh.2017.02.016] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 23.8] [Reference Citation Analysis]
171 Bashir NS, Walters TD, Griffiths AM, Ito S, Ungar WJ. Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease. Inflamm Bowel Dis 2020;26:1239-50. [PMID: 31728510 DOI: 10.1093/ibd/izz267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
172 Yamamoto T, Shimoyama T. Monitoring and detection of disease recurrence after resection for Crohn’s disease: the role of non-invasive fecal biomarkers. Expert Review of Gastroenterology & Hepatology 2017;11:899-909. [DOI: 10.1080/17474124.2017.1356226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
173 Zheng XB, Liu HS, Zhang LJ, Liu XH, Zhong XL, Zhou C, Hu T, Wu XR, Hu JC, Lian L, Deng QL, Chen YF, Ke J, He XW, Wu XJ, He XS, Lan P. Engulfment and Cell Motility Protein 1 Protects Against DSS-induced Colonic Injury in Mice via Rac1 Activation. J Crohns Colitis 2019;13:100-14. [PMID: 30219846 DOI: 10.1093/ecco-jcc/jjy133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
174 Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, Mckee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D’haens G. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease. Aliment Pharmacol Ther 2019;49:1401-9. [DOI: 10.1111/apt.15250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
175 Rivière P, D'Haens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D. Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. Am J Gastroenterol 2021;116:134-41. [PMID: 33177349 DOI: 10.14309/ajg.0000000000000834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
177 Nakase H, Hirano T, Wagatsuma K, Ichimiya T, Yamakawa T, Yokoyama Y, Hayashi Y, Hirayama D, Kazama T, Yoshii S, Yamano HO. Artificial intelligence-assisted endoscopy changes the definition of mucosal healing in ulcerative colitis. Dig Endosc. 2020;. [PMID: 32909283 DOI: 10.1111/den.13825] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
178 Karstensen JG, Săftoiu A, Brynskov J, Hendel J, Ciocalteu A, Klausen P, Klausen TW, Riis LB, Vilmann P. Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). Gastrointest Endosc 2016;84:279-286.e1. [PMID: 26945556 DOI: 10.1016/j.gie.2016.01.069] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
179 Wong J, Garcia-Carbonell R, Zelic M, Ho SB, Boland BS, Yao SJ, Desai SA, Das S, Planell N, Harris PA, Font-Burgada J, Taniguchi K, Bertin J, Salas A, Pasparakis M, Gough PJ, Kelliher M, Karin M, Guma M. RIPK1 Mediates TNF-Induced Intestinal Crypt Apoptosis During Chronic NF-κB Activation. Cell Mol Gastroenterol Hepatol 2020;9:295-312. [PMID: 31606566 DOI: 10.1016/j.jcmgh.2019.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
180 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
181 Seidelin JB, Larsen S, Linnemann D, Vainer B, Coskun M, Troelsen JT, Nielsen OH. Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. Am J Physiol Gastrointest Liver Physiol. 2015;308:G92-G99. [PMID: 25394657 DOI: 10.1152/ajpgi.00089.2014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
182 Svrcek M, Borralho Nunes P, Villanacci V, Beaugerie L, Rogler G, De Hertogh G, Tripathi M, Feakins R; H-ECCO group. Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of Inflammation. J Crohns Colitis 2018;12:1486-98. [PMID: 30202940 DOI: 10.1093/ecco-jcc/jjy132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
183 Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
184 Power KA, Lu JT, Monk JM, Lepp D, Wu W, Zhang C, Liu R, Tsao R, Robinson LE, Wood GA, Wolyn DJ. Purified rutin and rutin-rich asparagus attenuates disease severity and tissue damage following dextran sodium sulfate-induced colitis. Mol Nutr Food Res 2016;60:2396-412. [PMID: 27349947 DOI: 10.1002/mnfr.201500890] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
185 Zorzi F, Ghosh S, Chiaramonte C, Lolli E, Ventura M, Onali S, De Cristofaro E, Fantini MC, Biancone L, Monteleone G, Calabrese E. Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn’s Disease. Clinical Gastroenterology and Hepatology 2020;18:2030-7. [DOI: 10.1016/j.cgh.2019.10.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
186 Vasudevan A, Bruining DH, Loftus EV Jr, Faubion W, Ehman EC, Raffals L. Approach to medical therapy in perianal Crohn’s disease. World J Gastroenterol 2021; 27(25): 3693-3704 [PMID: 34321838 DOI: 10.3748/wjg.v27.i25.3693] [Reference Citation Analysis]
187 Chiba M, Tsuji T, Komatsu M. Conflicting results on the efficacy of enteral nutrition during infliximab maintenance therapy for Crohn's disease are correct. Dig Dis Sci 2014;59:227-8. [PMID: 24282058 DOI: 10.1007/s10620-013-2954-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
188 Nomura E, Sujino T, Hosoe N, Yoshimatsu Y, Tanemoto S, Takabayashi K, Mutaguchi M, Shimoda M, Naganuma M, Ogata H, Kanai T. Characteristics of the Mucosal Surface on Scanning Electron Microscopy in Patients with Remitting Ulcerative Colitis. Dig Dis Sci 2021;66:3141-8. [PMID: 32955688 DOI: 10.1007/s10620-020-06609-4] [Reference Citation Analysis]
189 Kavitt RT, Hirano I, Vaezi MF. Diagnosis and Treatment of Eosinophilic Esophagitis in Adults. Am J Med. 2016;129:924-934. [PMID: 27155108 DOI: 10.1016/j.amjmed.2016.04.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
190 Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol 2013;7:341-51. [PMID: 23639092 DOI: 10.1586/egh.13.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
191 Macé V, Ahluwalia A, Coron E, Le Rhun M, Boureille A, Bossard C, Mosnier JF, Matysiak-Budnik T, Tarnawski AS. Confocal laser endomicroscopy: a new gold standard for the assessment of mucosal healing in ulcerative colitis. J Gastroenterol Hepatol. 2015;30 Suppl 1:85-92. [PMID: 25827810 DOI: 10.1111/jgh.12748] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
192 Pedersen J, LaCasse EC, Seidelin JB, Coskun M, Nielsen OH. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med. 2014;20:652-665. [PMID: 25282548 DOI: 10.1016/j.molmed.2014.09.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 9.9] [Reference Citation Analysis]
193 Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol. 2014;49:674-682. [PMID: 23666424 DOI: 10.1007/s00535-013-0829-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
194 Leoni G, Neumann PA, Sumagin R, Denning TL, Nusrat A. Wound repair: role of immune-epithelial interactions. Mucosal Immunol 2015;8:959-68. [PMID: 26174765 DOI: 10.1038/mi.2015.63] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 22.8] [Reference Citation Analysis]
195 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 18.0] [Reference Citation Analysis]
196 Suzuki K, Arumugam S, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Mizumoto S, Sugahara K, Atreya R, Neurath MF, Watanabe K, Hashiguchi T, Yoneyama H, Asakura H. Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One 2016;11:e0158967. [PMID: 27410685 DOI: 10.1371/journal.pone.0158967] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
197 Kinugasa T, Akagi Y. Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol 2016; 8(4): 351-357 [PMID: 27096030 DOI: 10.4251/wjgo.v8.i4.351] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
198 Morita Y, Imaeda H, Nishida A, Inatomi O, Bamba S, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. J Gastroenterol Hepatol. 2016;31:1831-1836. [PMID: 27043158 DOI: 10.1111/jgh.13400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
199 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Reference Citation Analysis]
200 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 556] [Article Influence: 227.3] [Reference Citation Analysis]
201 Neumann H, Fujishiro M, Wilcox CM, Mönkemüller K. Present and future perspectives of virtual chromoendoscopy with i-scan and optical enhancement technology. Dig Endosc 2014;26 Suppl 1:43-51. [PMID: 24373000 DOI: 10.1111/den.12190] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
202 Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58-76. [PMID: 24157534 DOI: 10.1016/j.addr.2013.10.001] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 15.3] [Reference Citation Analysis]
203 Lehtola E, Haapamäki J, Färkkilä MA. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up. Scand J Gastroenterol 2016;51:1476-81. [PMID: 27686143 DOI: 10.1080/00365521.2016.1218539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
204 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 54.0] [Reference Citation Analysis]
205 Sathananthan D, Rajagopalan A, Van De Ven L, Martin S, Fon J, Costello S, Bryant RV. Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. JGH Open 2020;4:273-9. [PMID: 32280777 DOI: 10.1002/jgh3.12269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
206 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 471] [Article Influence: 59.9] [Reference Citation Analysis]
207 Fröhling M, Tepasse P, Intemann J, Sambale M, Sherwood J, Paruzel P, Tiemeyer NM, Nowacki TM, Brückner M, Mennigen R, Lügering A, Echtermeyer F, Pap T, Stratis A, Bettenworth D. Syndecan-4 Modulates Epithelial Gut Barrier Function and Epithelial Regeneration in Experimental Colitis. Inflamm Bowel Dis 2018;24:2579-89. [PMID: 30053064 DOI: 10.1093/ibd/izy248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
208 Waldner MJ, Rath T, Schürmann S, Bojarski C, Atreya R. Imaging of Mucosal Inflammation: Current Technological Developments, Clinical Implications, and Future Perspectives. Front Immunol 2017;8:1256. [PMID: 29075256 DOI: 10.3389/fimmu.2017.01256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
209 Neurath MF, Finotto S. IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine Growth Factor Rev 2016;29:93-9. [PMID: 26976761 DOI: 10.1016/j.cytogfr.2016.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
210 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-Matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019;2:e35-63. [PMID: 31294379 DOI: 10.1093/jcag/gwz018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
211 Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2927-36. [PMID: 23867874 DOI: 10.1097/MIB.0b013e31829aad16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
212 Arai M, Naganuma M, Sugimoto S, Kiyohara H, Ono K, Mori K, Saigusa K, Nanki K, Mutaguchi M, Mizuno S, Bessho R, Nakazato Y, Hosoe N, Matsuoka K, Inoue N, Ogata H, Iwao Y, Kanai T. The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission. J Crohns Colitis. 2016;10:1303-1309. [PMID: 27194529 DOI: 10.1093/ecco-jcc/jjw104] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
213 Liu S, You Y, Ruan G, Zhou L, Chen D, Wu D, Yan X, Zhang S, Zhou W, Li J, Qian J. The Long-Term Clinical and Endoscopic Outcomes of Cronkhite-Canada Syndrome. Clin Transl Gastroenterol. 2020;11:e00167. [PMID: 32352683 DOI: 10.14309/ctg.0000000000000167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
214 王承党, 郭晓雄. 炎症性肠病治疗的理想目标: 深度缓解的意义和对策. 世界华人消化杂志 2015; 23(24): 3824-3830 [DOI: 10.11569/wcjd.v23.i24.3824] [Reference Citation Analysis]
215 Paredes JM, Moreno N, Latorre P, Ripollés T, Martinez MJ, Vizuete J, Moreno-osset E. Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s Disease. Dig Dis Sci 2019;64:2600-6. [DOI: 10.1007/s10620-019-05567-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
216 Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:155-161. [PMID: 24909809 DOI: 10.1016/j.semarthrit.2014.05.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
217 Nakarai A, Kato J, Hiraoka S, Takashima S, Takei D, Inokuchi T, Sugihara Y, Takahara M, Harada K, Okada H. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse. World J Gastroenterol 2016; 22(21): 5079-5087 [PMID: 27275100 DOI: 10.3748/wjg.v22.i21.5079] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
218 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
219 Shin J, Kong SM, Seong G, Kim YH. What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission? Int J Colorectal Dis 2020;35:2249-55. [PMID: 32749515 DOI: 10.1007/s00384-020-03705-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
221 Gaowa A, Park EJ, Kawamoto E, Qin Y, Shimaoka M. Recombinant soluble thrombomodulin accelerates epithelial stem cell proliferation in mouse intestinal organoids and promotes the mucosal healing in colitis. J Gastroenterol Hepatol 2021. [PMID: 34370890 DOI: 10.1111/jgh.15656] [Reference Citation Analysis]
222 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 580] [Cited by in F6Publishing: 463] [Article Influence: 82.9] [Reference Citation Analysis]
223 Florholmen J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:43-52. [PMID: 25523555 DOI: 10.3109/00365521.2014.977943] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
224 Scionti A, Di Maurizio M, Basile M, Bernardini A, Miccoli M, Lionetti P, Defilippi C, Caramella D. Quantitative Analysis of Apparent Diffusion Coefficient for Disease Assessment in Paediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2019;68:353-9. [DOI: 10.1097/mpg.0000000000002178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Soendergaard C, Young JA, Kopchick JJ. Growth Hormone Resistance-Special Focus on Inflammatory Bowel Disease. Int J Mol Sci 2017;18:E1019. [PMID: 28486400 DOI: 10.3390/ijms18051019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
226 Han J, Yu C, Souza RF, Theiss AL. Prohibitin 1 modulates mitochondrial function of Stat3. Cell Signal. 2014;26:2086-2095. [PMID: 24975845 DOI: 10.1016/j.cellsig.2014.06.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
227 Flores AI, Gómez-Gómez GJ, Masedo-González &, Martínez-Montiel MP. Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy? World J Stem Cells 2015; 7(2): 343-351 [PMID: 25815119 DOI: 10.4252/wjsc.v7.i2.343] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
228 Andújar I, Ríos JL, Giner RM, Recio MC. Shikonin promotes intestinal wound healing in vitro via induction of TGF-β release in IEC-18 cells. Eur J Pharm Sci 2013;49:637-41. [PMID: 23727294 DOI: 10.1016/j.ejps.2013.05.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
229 Broide E, Eindor-abarbanel A, Naftali T, Shirin H, Shalem T, Richter V, Matalon S, Leshno M. Early Surgery Versus Biologic Therapy in Limited Nonstricturing Ileocecal Crohn’s Disease—A Decision-making Analysis. Inflammatory Bowel Diseases 2020;26:1648-57. [DOI: 10.1093/ibd/izz282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Yu Y, Chen KC, Chen J. Exclusive enteral nutrition versus corticosteroids for treatment of pediatric Crohn's disease: a meta-analysis. World J Pediatr. 2019;15:26-36. [PMID: 30666565 DOI: 10.1007/s12519-018-0204-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
231 Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore) 2021;100:e24717. [PMID: 33578614 DOI: 10.1097/MD.0000000000024717] [Reference Citation Analysis]
232 Rodriguez-Nogales A, Lozano-Pérez AA, Aznar-Cervantes SD, Algieri F, Garrido-Mesa J, Garrido-Mesa N, Vezza T, Utrilla MP, Cenis JL, Rodríguez-Cabezas ME, Gálvez J. Effect of aqueous and particulate silk fibroin in a rat model of experimental colitis. Int J Pharm 2016;511:1-9. [PMID: 27363935 DOI: 10.1016/j.ijpharm.2016.06.120] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
233 Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:580-6. [PMID: 30165638 DOI: 10.1093/ibd/izy272] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
234 Rath T, Tontini GE, Neurath MF, Neumann H. From the surface to the single cell: Novel endoscopic approaches in inflammatory bowel disease. World J Gastroenterol 2015; 21(40): 11260-11272 [PMID: 26523101 DOI: 10.3748/wjg.v21.i40.11260] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
235 Shi HY, Chan FK, Tsang SW, Hui YT, Sze SF, Ching JY, Chung T, Iu CY, Lo FH, Shan EH, Li MK, Wu JC, Sung JJ, Ng SC. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2015;21:840-6. [PMID: 25738375 DOI: 10.1097/MIB.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
236 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
237 Deng F, Yan J, Lu J, Luo M, Xia P, Liu S, Wang X, Zhi F, Liu D. M2 Macrophage-Derived Exosomal miR-590-3p Attenuates DSS-Induced Mucosal Damage and Promotes Epithelial Repair via the LATS1/YAP/ β-Catenin Signalling Axis. J Crohns Colitis 2021;15:665-77. [PMID: 33075119 DOI: 10.1093/ecco-jcc/jjaa214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
238 Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) 2014;1:24. [PMID: 25593900 DOI: 10.3389/fmed.2014.00024] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
239 Palone F, Vitali R, Cucchiara S, Pierdomenico M, Negroni A, Aloi M, Nuti F, Felice C, Armuzzi A, Stronati L. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:1448-1457. [PMID: 24983978 DOI: 10.1097/mib.0000000000000113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
240 Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf) 2020;8:306-11. [PMID: 32843978 DOI: 10.1093/gastro/goz041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
242 Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, Zundler S. Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. Front Med (Lausanne) 2021;8:643973. [PMID: 33834033 DOI: 10.3389/fmed.2021.643973] [Reference Citation Analysis]
243 Roy S, Esmaeilniakooshkghazi A, Patnaik S, Wang Y, George SP, Ahrorov A, Hou JK, Herron AJ, Sesaki H, Khurana S. Villin-1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation. Gastroenterology 2018;154:1405-1420.e2. [PMID: 29274870 DOI: 10.1053/j.gastro.2017.12.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
244 Uchiyama K, Takagi T, Kashiwagi S, Toyokawa Y, Tanaka M, Hotta Y, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Handa O, Konishi H, Kishimoto M, Yagi N, Naito Y, Itoh Y. Assessment of Endoscopic Mucosal Healing of Ulcerative Colitis Using Linked Colour Imaging, a Novel Endoscopic Enhancement System. J Crohns Colitis. 2017;11:963-969. [PMID: 28333209 DOI: 10.1093/ecco-jcc/jjx026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
245 Kaukinen K, Lindfors K, Mäki M. Advances in the treatment of coeliac disease: an immunopathogenic perspective. Nat Rev Gastroenterol Hepatol 2014;11:36-44. [DOI: 10.1038/nrgastro.2013.141] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
246 Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K, Toya Y, Asakura K, Gonai T, Sugai T, Matsumoto T. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol 2018; 24(38): 4384-4392 [PMID: 30344422 DOI: 10.3748/wjg.v24.i38.4384] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
247 Ye X, Sun M. AGR2 ameliorates tumor necrosis factor-α-induced epithelial barrier dysfunction via suppression of NF-κB p65-mediated MLCK/p-MLC pathway activation. Int J Mol Med 2017;39:1206-14. [PMID: 28339048 DOI: 10.3892/ijmm.2017.2928] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
248 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
249 Singh S, Chowdhry M, Umar S, Bilal M, Clarke K. Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterol Rep (Oxf) 2018;6:61-4. [PMID: 29479445 DOI: 10.1093/gastro/gox005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
250 Kemp K, Sephton M. Aligning oral mesalazine treatment to health service priorities: guidance for nurses. Frontline Gastroenterol 2014;5:135-42. [PMID: 24683448 DOI: 10.1136/flgastro-2013-100357] [Reference Citation Analysis]
251 Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut. 2018;67:973-985. [PMID: 29437914 DOI: 10.1136/gutjnl-2017-315655] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 18.7] [Reference Citation Analysis]
252 Takenaka K, Ohtsuka K, Fujii T, Negi M, Suzuki K, Shimizu H, Oshima S, Akiyama S, Motobayashi M, Nagahori M, Saito E, Matsuoka K, Watanabe M. Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis. Gastroenterology. 2020;158:2150-2157. [PMID: 32060000 DOI: 10.1053/j.gastro.2020.02.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 50.0] [Reference Citation Analysis]
253 Luján-Sanchis M, Sanchis-Artero L, Larrey-Ruiz L, Peño-Muñoz L, Núñez-Martínez P, Castillo-López G, González-González L, Clemente CB, Albert Antequera C, Durá-Ayet A, Sempere-Garcia-Argüelles J. Current role of capsule endoscopy in Crohn’s disease. World J Gastrointest Endosc 2016; 8(17): 572-583 [PMID: 27668067 DOI: 10.4253/wjge.v8.i17.572] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
254 Eder P, Stawczyk-Eder K, Korybalska K, Czepulis N, Luczak J, Lykowska-Szuber L, Krela-Kazmierczak I, Linke K, Witowski J. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies. World J Gastroenterol 2017; 23(1): 135-140 [PMID: 28104989 DOI: 10.3748/wjg.v23.i1.135] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
255 Walsh A, Palmer R, Travis S. Mucosal Healing As a Target of Therapy for Colonic Inflammatory Bowel Disease and Methods to Score Disease Activity. Gastrointestinal Endoscopy Clinics of North America 2014;24:367-78. [DOI: 10.1016/j.giec.2014.03.005] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 9.9] [Reference Citation Analysis]
256 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
257 Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443-1451; quiz e88-9. [PMID: 24462626 DOI: 10.1016/j.cgh.2014.01.021] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 13.4] [Reference Citation Analysis]
258 Farkas K, Lakatos PL, Szűcs M, Pallagi-Kunstár &, Bálint A, Nagy F, Szepes Z, Vass N, Kiss LS, Wittmann T, Molnár T. Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol 2014; 20(11): 2995-3001 [PMID: 24659890 DOI: 10.3748/wjg.v20.i11.2995] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
259 Maeda Y, Kudo SE, Mori Y, Misawa M, Ogata N, Sasanuma S, Wakamura K, Oda M, Mori K, Ohtsuka K. Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video). Gastrointest Endosc. 2019;89:408-415. [PMID: 30268542 DOI: 10.1016/j.gie.2018.09.024] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 25.0] [Reference Citation Analysis]
260 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
261 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 150] [Article Influence: 28.7] [Reference Citation Analysis]
262 Gavrilescu O, Prelipcean CC, Dranga M, Soponaru C, Mihai C. The specialized educational and psychological counseling in inflammatory bowel disease patients - a target or a challenge? Turk J Gastroenterol 2020;31:760-6. [PMID: 33361038 DOI: 10.5152/tjg.2020.19669] [Reference Citation Analysis]
263 Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology 2016;5:e118. [PMID: 28090320 DOI: 10.1038/cti.2016.75] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
264 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Watanabe K, Ito M, Komatsu M, Sugawara T. Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial. Perm J 2017;21:17-009. [PMID: 29035182 DOI: 10.7812/TPP/17-009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
265 Collins PD. Video capsule endoscopy in inflammatory bowel disease. World J Gastrointest Endosc 2016; 8(14): 477-488 [PMID: 27499830 DOI: 10.4253/wjge.v8.i14.477] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
266 Rajagopalan A, Sathananthan D, An YK, Van De Ven L, Martin S, Fon J, Costello SP, Begun J, Bryant RV. Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. JGH Open. 2020;4:267-272. [PMID: 32280776 DOI: 10.1002/jgh3.12268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
267 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
268 Obraztsov IV, Shirokikh KE, Obraztsova OI, Shapina MV, Wang MH, Khalif IL. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients. Inflamm Bowel Dis 2019;25:524-31. [PMID: 30544140 DOI: 10.1093/ibd/izy358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
269 Shi HY, Chan FKL, Higashimori A, Kyaw M, Ching JYL, Chan HCH, Chan JCH, Chan AWH, Lam KLY, Tang RSY. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc. 2017;86:1139-1146.e6. [PMID: 28713062 DOI: 10.1016/j.gie.2017.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
270 Vanhaecke T, Aubert P, Grohard P, Durand T, Hulin P, Paul-gilloteaux P, Fournier A, Docagne F, Ligneul A, Fressange-mazda C, Naveilhan P, Boudin H, Le Ruyet P, Neunlist M. L. fermentum CECT 5716 prevents stress-induced intestinal barrier dysfunction in newborn rats. Neurogastroenterol Motil 2017;29:e13069. [DOI: 10.1111/nmo.13069] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
271 Al-Sadi R, Dharmaprakash V, Nighot P, Guo S, Nighot M, Do T, Ma TY. Bifidobacterium bifidum Enhances the Intestinal Epithelial Tight Junction Barrier and Protects against Intestinal Inflammation by Targeting the Toll-like Receptor-2 Pathway in an NF-κB-Independent Manner. Int J Mol Sci 2021;22:8070. [PMID: 34360835 DOI: 10.3390/ijms22158070] [Reference Citation Analysis]
272 Kiesslich R, Neurath MF. Advanced endoscopy imaging in inflammatory bowel diseases. Gastrointest Endosc. 2017;85:496-508. [PMID: 27816496 DOI: 10.1016/j.gie.2016.10.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
273 Liu S, Xu A, Gao Y, Xie Y, Liu Z, Sun M, Mao H, Wang X. Graphene oxide exacerbates dextran sodium sulfate-induced colitis via ROS/AMPK/p53 signaling to mediate apoptosis. J Nanobiotechnology 2021;19:85. [PMID: 33766052 DOI: 10.1186/s12951-021-00832-5] [Reference Citation Analysis]
274 Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, Schoeman MN, Mountifield R, Tee D, Travis SPL, Andrews JM. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. J Gastroenterol Hepatol. 2018;33:599-607. [PMID: 28806471 DOI: 10.1111/jgh.13923] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
275 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 74] [Article Influence: 46.0] [Reference Citation Analysis]
276 Guo J, Xu L, Teng X, Sun M. MicroRNA-7-5p regulates the proliferation and migration of intestinal epithelial cells by targeting trefoil factor 3 via inhibiting the phosphoinositide 3-kinase/Akt signalling pathway. Int J Mol Med 2017;40:1435-43. [PMID: 28901375 DOI: 10.3892/ijmm.2017.3120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
277 Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015;16:63-78. [PMID: 25418125 DOI: 10.1517/14656566.2015.981525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
278 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 170] [Article Influence: 31.7] [Reference Citation Analysis]
279 Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease? Best Pract Res Clin Gastroenterol 2019;38-39:101601. [PMID: 31327406 DOI: 10.1016/j.bpg.2019.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
280 Olivera P, Danese S, Peyrin-biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 14.4] [Reference Citation Analysis]
281 Buchner AM. Confocal Laser Endomicroscopy in the Evaluation of Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1302-12. [PMID: 30877772 DOI: 10.1093/ibd/izz021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
282 Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response. Gastroenterol Res Pract 2016;2016:8168695. [PMID: 26819611 DOI: 10.1155/2016/8168695] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
283 Suzuki K, Yoneyama H. New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease. Ann Transl Med 2017;5:191. [PMID: 28616406 DOI: 10.21037/atm.2017.03.65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
284 Ataca P, Soyturk M, Karaman M, Unlu M, Sagol O, Dervis Hakim G, Yilmaz O. Nilotinib-mediated mucosal healing in a rat model of colitis. World J Gastroenterol 2013; 19(37): 6237-6244 [PMID: 24115822 DOI: 10.3748/wjg.v19.i37.6237] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Teruel AH, Gonzalez-Alvarez I, Bermejo M, Merino V, Marcos MD, Sancenon F, Gonzalez-Alvarez M, Martinez-Mañez R. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. Int J Mol Sci 2020;21:E6502. [PMID: 32899548 DOI: 10.3390/ijms21186502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
286 Yu Z, Yue B, Ding L, Luo X, Ren Y, Zhang J, Mani S, Wang Z, Dou W. Activation of PXR by Alpinetin Contributes to Abrogate Chemically Induced Inflammatory Bowel Disease. Front Pharmacol 2020;11:474. [PMID: 32372959 DOI: 10.3389/fphar.2020.00474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
287 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
288 Takenaka K, Kitazume Y, Fujii T, Tsuchiya K, Watanabe M, Ohtsuka K. Objective evaluation for treat to target in Crohn's disease. J Gastroenterol 2020;55:579-87. [PMID: 32130521 DOI: 10.1007/s00535-020-01678-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
289 Turvill J, Rook L, Rawle M, Robins G, Smale S, Kant P, Phillips A. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterol 2017;8:183-8. [PMID: 28839907 DOI: 10.1136/flgastro-2016-100780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
290 Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep 2018;8:9119. [PMID: 29904166 DOI: 10.1038/s41598-018-27353-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
291 Archer TP, Moran GW, Ghosh S. Tofacitinib in ulcerative colitis. Immunotherapy 2016;8:495-502. [DOI: 10.2217/imt-2015-0031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
292 Vidal-Lletjós S, Andriamihaja M, Blais A, Grauso M, Lepage P, Davila AM, Viel R, Gaudichon C, Leclerc M, Blachier F, Lan A. Dietary Protein Intake Level Modulates Mucosal Healing and Mucosa-Adherent Microbiota in Mouse Model of Colitis. Nutrients 2019;11:E514. [PMID: 30823387 DOI: 10.3390/nu11030514] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
293 Sexton KA, Walker JR, Graff LA, Bernstein MT, Beatie B, Miller N, Sargent M, Targownik LE. Evidence of Bidirectional Associations Between Perceived Stress and Symptom Activity: A Prospective Longitudinal Investigation in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2017;23:473-83. [DOI: 10.1097/mib.0000000000001040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
294 Turvill J. Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy. Frontline Gastroenterol 2014;5:167-75. [PMID: 28839766 DOI: 10.1136/flgastro-2014-100441] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
295 Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19. [PMID: 24084775 DOI: 10.1038/mi.2013.73] [Cited by in Crossref: 192] [Cited by in F6Publishing: 188] [Article Influence: 24.0] [Reference Citation Analysis]
296 Basaranoglu M, Ertan A, Mathew S, Najjar SM, Ala A, Demirbag AE, Senturk H. Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey. J Gastrointest Dig Syst 2016;6:467. [PMID: 29057149 DOI: 10.4172/2161-069X.1000467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
297 Chiba M, Nakane K, Takayama Y, Sugawara K, Ohno H, Ishii H, Tsuda S, Tsuji T, Komatsu M, Sugawara T. Development and Application of a Plant-Based Diet Scoring System for Japanese Patients with Inflammatory Bowel Disease. Perm J 2016;20:16-019. [PMID: 27768566 DOI: 10.7812/TPP/16-019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
298 Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
299 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 162] [Cited by in F6Publishing: 142] [Article Influence: 23.1] [Reference Citation Analysis]
300 Shen W, Cao L, Li Y, Cai X, Ge Y, Zhu W. Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn’s Disease. Diseases of the Colon & Rectum 2018;61:706-12. [DOI: 10.1097/dcr.0000000000001074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
301 Vogel H, Halpert D, Horoupian DS. Hypoplasia of posterior spinal roots and dorsal spinal tracts with arthrogryposis multiplex congenita. Acta Neuropathol. 1990;79:692-696. [PMID: 2360413 DOI: 10.1136/gutjnl-2013-304636] [Cited by in Crossref: 221] [Cited by in F6Publishing: 193] [Article Influence: 7.1] [Reference Citation Analysis]
302 Monk JM, Wu W, Hutchinson AL, Pauls P, Robinson LE, Power KA. Navy and black bean supplementation attenuates colitis-associated inflammation and colonic epithelial damage. J Nutr Biochem 2018;56:215-23. [PMID: 29631142 DOI: 10.1016/j.jnutbio.2018.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
303 Anzai S, Kawamoto A, Nagata S, Takahashi J, Kawai M, Kuno R, Kobayashi S, Watanabe S, Suzuki K, Shimizu H, Hiraguri Y, Takeoka S, Sugihara HY, Yui S, Oshima S, Watanabe M, Okamoto R. TGF-β promotes fetal gene expression and cell migration velocity in a wound repair model of untransformed intestinal epithelial cells. Biochem Biophys Res Commun 2020;524:533-41. [PMID: 32014254 DOI: 10.1016/j.bbrc.2020.01.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
304 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
305 Hundorfean G, Chiriac MT, Mihai S, Hartmann A, Mudter J, Neurath MF. Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflamm Bowel Dis 2017;24:35-44. [PMID: 29272480 DOI: 10.1093/ibd/izx012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
306 Buchner AM, Lichtenstein GR. How to Assess and Document Endoscopies in IBD Patients by Including Standard Scoring Systems. Inflamm Bowel Dis 2016;22:1010-9. [PMID: 26963565 DOI: 10.1097/MIB.0000000000000649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
307 Acovic A, Simovic Markovic B, Gazdic M, Arsenijevic A, Jovicic N, Gajovic N, Jovanovic M, Zdravkovic N, Kanjevac T, Harrell CR, Fellabaum C, Dolicanin Z, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Indoleamine 2,3-dioxygenase-dependent expansion of T-regulatory cells maintains mucosal healing in ulcerative colitis. Therap Adv Gastroenterol. 2018;11:1756284818793558. [PMID: 30159037 DOI: 10.1177/1756284818793558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
308 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
309 Farr L, Ghosh S, Jiang N, Watanabe K, Parlak M, Bucala R, Moonah S. CD74 Signaling Links Inflammation to Intestinal Epithelial Cell Regeneration and Promotes Mucosal Healing. Cell Mol Gastroenterol Hepatol 2020;10:101-12. [PMID: 32004754 DOI: 10.1016/j.jcmgh.2020.01.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
310 Naganuma M, Hosoe N, Kanai T, Ogata H. Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med 2015;30:271-8. [PMID: 25995657 DOI: 10.3904/kjim.2015.30.3.271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
311 Choi SY, Choi YO, Choe YH, Kang B. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. J Korean Med Sci 2020;35:e114. [PMID: 32329259 DOI: 10.3346/jkms.2020.35.e114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
312 Agrawal M, Colombel JF. Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat? Gastrointest Endosc Clin N Am. 2019;29:421-436. [PMID: 31078245 DOI: 10.1016/j.giec.2019.02.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 11.5] [Reference Citation Analysis]
313 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
314 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 290] [Article Influence: 180.5] [Reference Citation Analysis]
315 Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1037-48. [PMID: 24788216 DOI: 10.1097/MIB.0000000000000049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
316 Soendergaard C, Kvist PH, Thygesen P, Reslow M, Nielsen OH, Kopchick JJ, Holm TL. Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. Int J Mol Sci. 2017;18:2046. [PMID: 28946616 DOI: 10.3390/ijms18102046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
317 Yong HM, Park SJ, Jeon SR, Park H, Kim HG, Lee TH, Park J, Kim JO, Lee JS, Ko BM, Goong HJ, Park S. Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis. Medicine (Baltimore) 2021;100:e27065. [PMID: 34449501 DOI: 10.1097/MD.0000000000027065] [Reference Citation Analysis]
318 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
319 Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416-1423. [PMID: 24162591 DOI: 10.1136/gutjnl-2013-305763] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 9.9] [Reference Citation Analysis]
320 Mack DR, Benchimol EI, Critch J, deBruyn J, Tse F, Moayyedi P, Church P, Deslandres C, El-matary W, Huynh H, Jantchou P, Lawrence S, Otley A, Sherlock M, Walters T, Kappelman MD, Sadowski D, Marshall JK, Griffiths A. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. Gastroenterology 2019;157:320-48. [DOI: 10.1053/j.gastro.2019.03.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
321 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 144] [Cited by in F6Publishing: 123] [Article Influence: 36.0] [Reference Citation Analysis]
322 Purup S, Nielsen SD, Le TT, Bertelsen H, Sørensen J, Larsen LB. Wound Healing Properties of Commercial Milk Hydrolysates in Intestinal Cells. Int J Pept Res Ther 2019;25:483-91. [DOI: 10.1007/s10989-018-9692-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
323 Zhang J, Ding L, Wang B, Ren G, Sun A, Deng C, Wei X, Mani S, Wang Z, Dou W. Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activation. J Pharmacol Exp Ther 2015;352:315-24. [PMID: 25472953 DOI: 10.1124/jpet.114.218750] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
324 Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. Gastroenterol Hepatol 2021;44:87-95. [PMID: 32680729 DOI: 10.1016/j.gastrohep.2020.04.015] [Reference Citation Analysis]
325 Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:946-51. [PMID: 24451222 DOI: 10.1097/01.MIB.0000441349.40193.aa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
326 Hasegawa M, Parkos CA, Nusrat A. WD40 Repeat Protein 26 Negatively Regulates Formyl Peptide Receptor-1 Mediated Wound Healing in Intestinal Epithelial Cells. Am J Pathol 2020;190:2029-38. [PMID: 32958140 DOI: 10.1016/j.ajpath.2020.06.005] [Reference Citation Analysis]
327 Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL. Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. Journal of Crohn's and Colitis 2018;12:1151-7. [DOI: 10.1093/ecco-jcc/jjy081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
328 Rantalainen M, Bjerrum JT, Olsen J, Nielsen OH, Wang Y. Integrative Transcriptomic and Metabonomic Molecular Profiling of Colonic Mucosal Biopsies Indicates a Unique Molecular Phenotype for Ulcerative Colitis. J Proteome Res 2015;14:479-90. [DOI: 10.1021/pr500699h] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
329 Bálint A, Farkas K, Szepes Z, Nagy F, Szűcs M, Tiszlavicz L, Bor R, Milassin Á, Rutka M, Fábián A, Molnár T. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. BMC Gastroenterol 2018;18:7. [PMID: 29310593 DOI: 10.1186/s12876-017-0725-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
330 Nidhi M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J. 2016;24:458-472. [PMID: 27330377 DOI: 10.1016/j.jsps.2014.10.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
331 Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016;18:123-30. [PMID: 28458507 DOI: 10.1016/j.tgie.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
332 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
333 Liu J, Dlugosz A, Neumann H. Beyond white light endoscopy: The role of optical biopsy in inflammatory bowel disease. World J Gastroenterol 2013; 19(43): 7544-7551 [PMID: 24282344 DOI: 10.3748/wjg.v19.i43.7544] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
334 Buttó LF, Haller D. Dysbiosis in intestinal inflammation: Cause or consequence. Int J Med Microbiol 2016;306:302-9. [PMID: 27012594 DOI: 10.1016/j.ijmm.2016.02.010] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 13.8] [Reference Citation Analysis]
335 Yang H, Feng R, Fu Q, Xu S, Hao X, Qiu Y, Feng T, Zeng Z, Chen M, Zhang S. Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-α-stimulated gene-6 in inflammatory bowel disease models. Cell Death Dis 2019;10:718. [PMID: 31558705 DOI: 10.1038/s41419-019-1957-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
336 Theede K, Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis. Inflamm Bowel Dis. 2016;22:1042-1048. [PMID: 26919460 DOI: 10.1097/mib.0000000000000736] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 19.3] [Reference Citation Analysis]
337 Kemp R, Dunn E, Schultz M. Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents. BioDrugs 2013;27:585-90. [PMID: 23749336 DOI: 10.1007/s40259-013-0045-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
338 Hunt JE, Holst JJ, Jeppesen PB, Kissow H. GLP-1 and Intestinal Diseases. Biomedicines 2021;9:383. [PMID: 33916501 DOI: 10.3390/biomedicines9040383] [Reference Citation Analysis]
339 Bevivino G, Monteleone G. Advances in understanding the role of cytokines in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2018;12:907-915. [PMID: 30024302 DOI: 10.1080/17474124.2018.1503053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
340 Peñate Medina T, Kolb JP, Hüttmann G, Huber R, Peñate Medina O, Ha L, Ulloa P, Larsen N, Ferrari A, Rafecas M, Ellrichmann M, Pravdivtseva MS, Anikeeva M, Humbert J, Both M, Hundt JE, Hövener JB. Imaging Inflammation - From Whole Body Imaging to Cellular Resolution. Front Immunol 2021;12:692222. [PMID: 34248987 DOI: 10.3389/fimmu.2021.692222] [Reference Citation Analysis]
341 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 14.3] [Reference Citation Analysis]
342 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
343 da Silva Moraes AC, de Freitas Moraes G, de Araújo ALE, Luiz RR, Elia C, Carneiro AJ, de Souza HSP. Abdominal ultrasonography with color Doppler analysis in the assessment of ileal Crohn's disease: comparison with magnetic resonance enterography. Intest Res 2019;17:227-36. [PMID: 30962408 DOI: 10.5217/ir.2018.00124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
344 Lozano-Pérez AA, Rodriguez-Nogales A, Ortiz-Cullera V, Algieri F, Garrido-Mesa J, Zorrilla P, Rodriguez-Cabezas ME, Garrido-Mesa N, Utrilla MP, De Matteis L, de la Fuente JM, Cenis JL, Gálvez J. Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats. Int J Nanomedicine 2014;9:4507-20. [PMID: 25285004 DOI: 10.2147/IJN.S68526] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
345 Naganuma M, Yahagi N, Bessho R, Ohno K, Arai M, Mutaguchi M, Mizuno S, Fujimoto A, Uraoka T, Shimoda M, Hosoe N, Ogata H, Kanai T. Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels. Endosc Int Open 2017;5:E76-82. [PMID: 28180151 DOI: 10.1055/s-0042-119393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
346 Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20(46): 17352-17359 [PMID: 25516646 DOI: 10.3748/wjg.v20.i46.17352] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
347 Tontini GE, Rimondi A, Vernero M, Neumann H, Vecchi M, Bezzio C, Cavallaro F. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. Therap Adv Gastroenterol 2021;14:17562848211017730. [PMID: 34178115 DOI: 10.1177/17562848211017730] [Reference Citation Analysis]
348 Colombel JF, Ordás I, Ullman T, Rutgeerts P, Chai A, O'Byrne S, Lu TT, Panés J. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology 2016;150:389-95.e3. [PMID: 26526713 DOI: 10.1053/j.gastro.2015.10.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
349 Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M. Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn´s disease. J Crohns Colitis 2021:jjab055. [PMID: 33773497 DOI: 10.1093/ecco-jcc/jjab055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
350 de Jong DC, Löwenberg M, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Gecse K, Ponsioen CY, D'Haens GR, Irving PM, Samaan MA. Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. Inflamm Bowel Dis 2019;25:937-44. [PMID: 30329045 DOI: 10.1093/ibd/izy325] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
351 Takahashi S, Yoshimura T, Ohkura T, Fujisawa M, Fushimi S, Ito T, Itakura J, Hiraoka S, Okada H, Yamamoto K, Matsukawa A. A Novel Role of Spred2 in the Colonic Epithelial Cell Homeostasis and Inflammation. Sci Rep 2016;6:37531. [PMID: 27869219 DOI: 10.1038/srep37531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
352 Lenz P, Brückner M, Ketelhut S, Heidemann J, Kemper B, Bettenworth D. Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing. J Vis Exp 2016. [PMID: 27685659 DOI: 10.3791/54460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
353 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 50.0] [Reference Citation Analysis]
354 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
355 Vidal-Lletjós S, Beaumont M, Tomé D, Benamouzig R, Blachier F, Lan A. Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa? Nutrients 2017;9:E310. [PMID: 28335546 DOI: 10.3390/nu9030310] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
356 Tenci M, Rossi S, Giannino V, Vigani B, Sandri G, Bonferoni MC, Daglia M, Longo LM, Macelloni C, Ferrari F. An In Situ Gelling System for the Local Treatment of Inflammatory Bowel Disease (IBD). The Loading of Maqui (Aristotelia Chilensis) Berry Extract as an Antioxidant and Anti-Inflammatory Agent. Pharmaceutics 2019;11:E611. [PMID: 31739619 DOI: 10.3390/pharmaceutics11110611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
357 Vidal-Lletjós S, Andriamihaja M, Blais A, Grauso M, Lepage P, Davila AM, Gaudichon C, Leclerc M, Blachier F, Lan A. Mucosal healing progression after acute colitis in mice. World J Gastroenterol 2019; 25(27): 3572-3589 [PMID: 31367158 DOI: 10.3748/wjg.v25.i27.3572] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
358 Cordes F, Brückner M, Lenz P, Veltman K, Glauben R, Siegmund B, Hengst K, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a Strengthens Intestinal Barrier Function and Follows the Course of Experimental Colitis: . Inflammatory Bowel Diseases 2016;22:2341-55. [DOI: 10.1097/mib.0000000000000917] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
359 Patel A, Panchal H, Dubinsky MC. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1600-4. [DOI: 10.1097/mib.0000000000001157] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
360 Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342-1348.e1. [PMID: 24407106 DOI: 10.1016/j.cgh.2013.12.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
361 Hou Q, Huang J, Ayansola H, Masatoshi H, Zhang B. Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. Front Immunol 2020;11:623691. [PMID: 33584726 DOI: 10.3389/fimmu.2020.623691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
362 Weinstein-Nakar I, Focht G, Church P, Walters TD, Abitbol G, Anupindi S, Berteloot L, Hulst JM, Ruemmele F, Lemberg DA, Leach ST, Cytter R, Greer ML, Griffiths AM, Turner D; ImageKids study group. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2018; 16: 1089-1097. e4. [PMID: 29501599 DOI: 10.1016/j.cgh.2018.01.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
363 Jädert C, Phillipson M, Holm L, Lundberg JO, Borniquel S. Preventive and therapeutic effects of nitrite supplementation in experimental inflammatory bowel disease. Redox Biol. 2014;2:73-81. [PMID: 24494186 DOI: 10.1016/j.redox.2013.12.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
364 Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. Medicine (Baltimore) 2016;95:e4799. [PMID: 27603389 DOI: 10.1097/MD.0000000000004799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Ortiz-Masiá D, Cosín-Roger J, Calatayud S, Hernández C, Alós R, Hinojosa J, Esplugues JV, Barrachina MD. M1 Macrophages Activate Notch Signalling in Epithelial Cells: Relevance in Crohn's Disease. J Crohns Colitis 2016;10:582-92. [PMID: 26802079 DOI: 10.1093/ecco-jcc/jjw009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
366 Goran L, Negreanu AM, Stemate A, Negreanu L. Capsule endoscopy: Current status and role in Crohn’s disease. World J Gastrointest Endosc 2018; 10(9): 184-192 [PMID: 30283601 DOI: 10.4253/wjge.v10.i9.184] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
367 Husam Al-Ani A, Christensen B. Endoscopic and histologic endpoints as treatment targets: Are we there yet? J Gastroenterol Hepatol 2021;36 Suppl 1:8-9. [PMID: 33817841 DOI: 10.1111/jgh.15447] [Reference Citation Analysis]
368 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 16.0] [Reference Citation Analysis]
369 Klenske E, Atreya R, Hartmann A, Fischer S, Hirschmann S, Zundler S, Iaccuci M, Neurath MF, Rath T. Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. Endosc Int Open 2019;7:E1018-26. [PMID: 31404439 DOI: 10.1055/a-0953-1334] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
370 Cameron FL, Altowati MA, Rogers P, Mcgrogan P, Anderson N, Bisset WM, Ahmed SF, Wilson DC, Russell RK. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2017;64:47-55. [DOI: 10.1097/mpg.0000000000001379] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
371 Keane TJ, Dziki J, Sobieski E, Smoulder A, Castleton A, Turner N, White LJ, Badylak SF. Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis. J Crohns Colitis. 2017;11:360-368. [PMID: 27543807 DOI: 10.1093/ecco-jcc/jjw149] [Cited by in Crossref: 16] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
372 Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, Wei X, Chou G, Wang ZT, Mani S. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr 2013;110:599-608. [PMID: 23506745 DOI: 10.1017/S0007114512005594] [Cited by in Crossref: 109] [Cited by in F6Publishing: 46] [Article Influence: 13.6] [Reference Citation Analysis]
373 Watanabe S, Nishimura R, Shirasaki T, Katsukura N, Hibiya S, Kirimura S, Negi M, Okamoto R, Matsumoto Y, Nakamura T, Watanabe M, Tsuchiya K. Schlafen 11 is a novel target for mucosal regeneration in Ulcerative Colitis. J Crohns Colitis 2021:jjab032. [PMID: 33596306 DOI: 10.1093/ecco-jcc/jjab032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
374 Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol 2015; 21(48): 13566-13573 [PMID: 26730169 DOI: 10.3748/wjg.v21.i48.13566] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
375 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
376 Tontini GE, Bisschops R, Neumann H. Endoscopic scoring systems for inflammatory bowel disease: pros and cons. Expert Rev Gastroenterol Hepatol. 2014;8:543-554. [PMID: 24650249 DOI: 10.1586/17474124.2014.899899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
377 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
378 Iablokov V, Hirota CL, Peplowski MA, Ramachandran R, Mihara K, Hollenberg MD, MacNaughton WK. Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem. 2014;289:34366-34377. [PMID: 25331954 DOI: 10.1074/jbc.M114.610485] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
379 Watanabe Y, Murata T, Amakawa M, Miyake Y, Handa T, Konishi K, Matsumura Y, Tanaka T, Takeuchi K. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. European Journal of Pharmacology 2015;754:179-89. [DOI: 10.1016/j.ejphar.2015.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
380 Park S, Abdi T, Gentry M, Laine L. Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016;111:1692-1701. [PMID: 27725645 DOI: 10.1038/ajg.2016.418] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 15.4] [Reference Citation Analysis]
381 Ojo BA, VanDussen KL, Rosen MJ. The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis. Inflamm Bowel Dis 2021:izab161. [PMID: 34251431 DOI: 10.1093/ibd/izab161] [Reference Citation Analysis]
382 Yim SM, Kim DH, Lee HJ, Jang HW, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci 2014;59:2529-35. [PMID: 24838499 DOI: 10.1007/s10620-014-3198-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
383 Gong W, Guo K, Zheng T, Fang M, Xie H, Li W, Hong Z, Ren H, Gu G, Wang G, Wu X, Wang Z, Ren J, Li J. Correlation between endoscopic and histological validated scoring indices in Crohn’s disease. Digestive and Liver Disease 2019;51:812-7. [DOI: 10.1016/j.dld.2019.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
384 Gottlieb K, Dawson J, Hussain F, Murray JA. Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. Gastroenterol Rep (Oxf) 2015;3:91-102. [PMID: 25725041 DOI: 10.1093/gastro/gov006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
385 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
386 E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. BMC Gastroenterol. 2020;20:35. [PMID: 32054445 DOI: 10.1186/s12876-020-1183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
387 Neumann H, Vieth M, Günther C, Neufert C, Kiesslich R, Grauer M, Atreya R, Neurath MF. Virtual chromoendoscopy for prediction of severity and disease extent in patients with inflammatory bowel disease: a randomized controlled study. Inflamm Bowel Dis. 2013;19:1935-1942. [PMID: 23839228 DOI: 10.1097/mib.0b013e318290550e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
388 Shinozaki S, Osawa H, Hayashi Y, Lefor AK, Yamamoto H. Linked color imaging for the detection of early gastrointestinal neoplasms. Therap Adv Gastroenterol 2019;12:1756284819885246. [PMID: 31700545 DOI: 10.1177/1756284819885246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
389 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 810] [Article Influence: 156.2] [Reference Citation Analysis]
390 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
391 Navas-López VM, Blasco-Alonso J, Lacasa Maseri S, Girón Fernández-Crehuet F, Serrano Nieto MJ, Vicioso Recio MI, Sierra Salinas C. [Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn’s disease in the era of biologics]. An Pediatr (Barc). 2014;Epub ahead of print. [PMID: 24704330 DOI: 10.1016/j.anpedi.2014.02.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
392 O'Toole A, Moss AC. Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease. Curr Gastroenterol Rep 2015;17:32. [PMID: 26188882 DOI: 10.1007/s11894-015-0453-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
393 Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y, Farcet JP, Delchier JC, Hüe S. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2016;40:90-98. [PMID: 26138132 DOI: 10.1016/j.clinre.2015.05.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
394 Costanzo M, Cesi V, Prete E, Negroni A, Palone F, Cucchiara S, Oliva S, Leter B, Stronati L. Krill oil reduces intestinal inflammation by improving epithelial integrity and impairing adherent-invasive Escherichia coli pathogenicity. Dig Liver Dis 2016;48:34-42. [PMID: 26493628 DOI: 10.1016/j.dld.2015.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
395 Kim JW, Kim HJ, Lee CK, Shim JJ, Jang JY, Dong SH, Kim BH, Chang YW, Chi SG. Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. Dig Dis Sci 2014;59:2947-57. [PMID: 25052149 DOI: 10.1007/s10620-014-3282-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
396 Ankersen DV, Carlsen K, Marker D, Munkholm P, Burisch J. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease: eHealth strategies for IBS and IBD. Journal of Gastroenterology and Hepatology 2017;32:27-31. [DOI: 10.1111/jgh.13691] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
397 Watanabe S, Hibiya S, Katsukura N, Kitagawa S, Sato A, Okamoto R, Watanabe M, Tsuchiya K. Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells. J Crohns Colitis 2021:jjab115. [PMID: 34180971 DOI: 10.1093/ecco-jcc/jjab115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
398 Macaluso FS, Maida M, Ventimiglia M, Renna S, Cottone M, Orlando A. Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Inflamm Bowel Dis 2019;25:987-97. [PMID: 30590590 DOI: 10.1093/ibd/izy365] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
399 Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y; OBSERV-IBD study group, the GETAID. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40-53. [PMID: 31165509 DOI: 10.1111/apt.15294] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
400 Stronati L, Palone F, Negroni A, Colantoni E, Mancuso AB, Cucchiara S, Cesi V, Isoldi S, Vitali R. Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions. Front Immunol 2019;10:939. [PMID: 31105713 DOI: 10.3389/fimmu.2019.00939] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
401 Bugatti S, Sakellariou G, Luvaro T, Greco MI, Manzo A. Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? Front Med (Lausanne) 2018;5:140. [PMID: 29868592 DOI: 10.3389/fmed.2018.00140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
402 Talapka P, Berkó A, Nagy LI, Chandrakumar L, Bagyánszki M, Puskás LG, Fekete &, Bódi N. Structural and molecular features of intestinal strictures in rats with Crohn's-like disease. World J Gastroenterol 2016; 22(22): 5154-5164 [PMID: 27298558 DOI: 10.3748/wjg.v22.i22.5154] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
403 Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin Pharmacol Ther 2019;106:945-54. [PMID: 31420861 DOI: 10.1002/cpt.1609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
404 Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen AM. Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-36. e1. [PMID: 26051392 DOI: 10.1016/j.cgh.2015.05.038] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 15.0] [Reference Citation Analysis]
405 Han J, Zhao Q, Basmadjian C, Désaubry L, Theiss AL. Flavaglines Ameliorate Experimental Colitis and Protect Against Intestinal Epithelial Cell Apoptosis and Mitochondrial Dysfunction. Inflamm Bowel Dis 2016;22:55-67. [PMID: 26398710 DOI: 10.1097/MIB.0000000000000592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
406 Suzuki K, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Sameshima Y, Fukushima T, Sugahara K, Atreya R, Neurath MF, Watanabe K, Yoneyama H, Asakura H. Phase 1 Clinical Study of siRNA Targeting Carbohydrate Sulphotransferase 15 in Crohn's Disease Patients with Active Mucosal Lesions. J Crohns Colitis 2017;11:221-8. [PMID: 27484097 DOI: 10.1093/ecco-jcc/jjw143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
407 杨刚, 牛俊坤, 李小玉, 张峰睿, 缪应雷. 干扰和过表达热休克转录因子2对肠上皮细胞凋亡和迁移的影响. 世界华人消化杂志 2015; 23(24): 3846-3859 [DOI: 10.11569/wcjd.v23.i24.3846] [Reference Citation Analysis]
408 Myrelid P, Salim SY, Darby T, Almer S, Melgar S, Andersson P, Söderholm JD. Effects of anti-inflammatory therapy on bursting pressure of colonic anastomosis in murine dextran sulfate sodium induced colitis. Scand J Gastroenterol 2015;50:991-1001. [PMID: 25861827 DOI: 10.3109/00365521.2014.964760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
409 Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51:11-21. [PMID: 26138071 DOI: 10.1007/s00535-015-1098-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 18.0] [Reference Citation Analysis]
410 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, van Assche G. [Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version)]. Rev Gastroenterol Mex 2014;79:263-89. [PMID: 25487134 DOI: 10.1016/j.rgmx.2014.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
411 Yoon JY, Cha JM, Lee CK, Park YS, Huh KC, Shin JE, Kim YS, Eun CS, Yoon SM, Cheon JH, Park YS, Ye BD, Lee Y, Kim Y, Kim HJ; MOSAIK study group of the Korean Association for the Study of Intestinal Diseases (KASID). Early course of newly diagnosed moderate-to-severe ulcerative colitis in Korea: Results from a hospital-based inception cohort study (MOSAIK). J Gastroenterol Hepatol 2021;36:2149-56. [PMID: 33555067 DOI: 10.1111/jgh.15435] [Reference Citation Analysis]
412 Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. Population Health Management for Inflammatory Bowel Disease. Gastroenterology 2018;154:37-45. [PMID: 29122544 DOI: 10.1053/j.gastro.2017.09.052] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
413 Neumann H, Fry LC, Nägel A, Neurath MF. Wireless capsule endoscopy of the small intestine: a review with future directions. Curr Opin Gastroenterol. 2014;30:463-471. [PMID: 25029549 DOI: 10.1097/mog.0000000000000101] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
414 Al-bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics of North America 2017;46:493-513. [DOI: 10.1016/j.gtc.2017.05.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]